Claims
- 1. A method of blocking amyloid toxicity in cells, said method comprising contacting said cells with an effective amount of at least one phenyl benzopyranone compound having Structure II, as follows:
- 2. The method of claim 1, wherein said amyloid toxicity is selected from the group consisting of amyloid beta peptide toxicity, amyloid prion protein toxicity, human amylin toxicity, amyloid A protein toxicity, transthyretin toxicity, and AL amyloid toxicity.
- 3. A method of decreasing amyloid protein production in cells, said method comprising contacting said cells with an effective amount of least one phenyl benzopyranone compound having Structure II, as follows:
- 4. The method of claim 3, wherein said amyloid protein is amyloid beta peptide, amyloid prion protein, islet amyloid protein, or amyloid A protein.
- 5. A method of inhibiting nerve cell death, said method comprising contacting said nerve cell with an effective amount of least one phenyl benzopyranone compound having Structure II, as follows:
- 6. A method for treating a disease condition in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of at least one phenyl benzopyranone compound having Structure II, as follows:
- 7. The method of claim 6, wherein said disease is Alzheimer's disease, prion disease, type II diabetes, amyloid A amyloidosis, familial transthyretin amyloidosis, or AL amyloidosis.
- 8. A method for preventing disease conditions, said method comprising administering to a patient at risk thereof a therapeutically effective amount of at least one phenyl benzopyranone compound having Structure II, as follows:
- 9. The method of claim 8, wherein said disease is Alzheimer's disease, prion disease, type II diabetes, amyloid A amyloidosis, familial transthyretin amyloidosis, or AL amyloidosis.
- 10. A method of increasing cell viability, said method comprising contacting said cell with an effective amount of at least one phenyl benzopyranone compound having Structure II, as follows:
- 11. The method according to claim 10, wherein said cell is a nerve cell, a glial cell, a pancreatic cell, an islets of Langerhans cell, an endothelial cell, or an endocrine cell.
- 12. A method of reducing amyloid deposits in a subject at risk thereof, said method comprising administering to said subject an effective amount of at least one phenyl benzopyranone compound having Structure II, as follows:
- 13. The method according to claim 12, wherein said amyloid deposits are deposits of one or more of amyloid beta peptide, prion protein, islet amyloid protein, amyloid A protein, transthyretin, or AL amyloid.
ACKNOWLEDGEMENT
[0001] This invention was made with government support under Grant No's. NS09658, NS28121, and 5 F32 NS10279-02 from the National Institutes of Health. The government may have certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09617147 |
Jul 2000 |
US |
Child |
10269477 |
Oct 2002 |
US |